High cost drugs in Latin America: access and barriers

References

• Augustovski F, Iglesias C, Manca A, et al. Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region. Pharmacoeconomics. 2009:27;919–929. DOI:10.2165/11313670-000000000-00000
   PubMed Web of Science ®Google Scholar
• Atun R, de Andrade LO, Almeida G, et al. Health-system reform and universal health coverage in Latin America. Lancet. 2015:385;1230–1247. DOI:10.1016/S0140-6736(14)61646-9
   PubMed Web of Science ®Google Scholar
• Lewis M, Penteado E, Malik AM. Brazil’s mixed public and private hospital system. World Hosp Health Serv. 2015;51:22–26.
   PubMedGoogle Scholar
• Barraza-Lloréns M, Bertozzi S, González-Pier E, et al. Addressing inequity in health and health care in Mexico. Health Aff. 2002;21:47–56.
   Web of Science ®Google Scholar
• Bastías G, Pantoja T, Leisewitz T, et al. Health care reform in Chile. CMAJ. 2008;179:1289–1292.
   PubMed Web of Science ®Google Scholar
• Sánchez-Moreno F. La inequidad en salud afecta el desarrollo en el Perú. Rev Peru Med Exp Salud Publica. 2013;30:676–682.
   PubMedGoogle Scholar
• López-Cevallos D, Chi C, Ortega F. Consideraciones para la transformación del sistema de salud del Ecuador desde una perspectiva de equidad. Rev Salud Pública. 2014;16:347–360.
   Google Scholar
• Hernández-Vásquez A, Rojas-Roque C, Prado-Galbarro FJ, et al. Satisfacción del usuario externo con la atención en establecimientos del Ministerio de Salud de Perú y sus factores asociados. Rev Peru Med Exp Salud Publica. 2019;36:620–628.
   PubMedGoogle Scholar
• González Anaya JA, García Cuéllar R. The transformation of the Mexican Social Security Institute (IMSS): progress and challenges. Health Syst Reform. 2015;1:189–199.
   PubMed Web of Science ®Google Scholar
• Sáenz MDR, Acosta M, Muiser J, et al. The health system of Costa Rica. Salud Publica Mex. 2011;53:s156–167.
   PubMed Web of Science ®Google Scholar
• Charlesworth A. Why is health care inflation greater than general inflation? J Health Serv Res Policy. 2014;19:129–130.
   PubMed Web of Science ®Google Scholar
• Rosselli D, Hernández-Galvis J. The impact of aging on the Colombian health system. Salud Pública Méx. 2016;58:595–596.
   PubMed Web of Science ®Google Scholar
• Arredondo A, Zúñiga A, Parada I. Health care costs and financial consequences of epidemiological changes in chronic diseases in Latin America: evidence from Mexico. Public Health. 2005;119:711–720.
   PubMed Web of Science ®Google Scholar
• Curioso WH. Building capacity and training for digital health: challenges and opportunities in Latin America. J Med Internet Res. 2019;21:e16513.
   PubMed Web of Science ®Google Scholar
• de Quirós FG B, Baum A, Lira A. Active participation and engagement of residents in clinical informatics. Appl Clin Inform. 2019;10:38–39.
   PubMed Web of Science ®Google Scholar
• Alves TF, Almeida FA, Brito FA, et al. Regulation and use of health information systems in Brazil and abroad: integrative review. Comput Inform Nurs. 2022;40:373–381.
   PubMed Web of Science ®Google Scholar
• Otero P, Perrin C, Geissbulher A, et al. Informatics education in low-resource settings. In: Berner ES, editor. Informatics education in healthcare. London: Springer; 2014. p. 197–222.
   Google Scholar
• Justo N, Espinoza MA, Ratto B, et al. Real-world evidence in healthcare decision making: global trends and case studies from Latin America. Value Health. 2019;22:739–749.
   PubMed Web of Science ®Google Scholar
• Fernández-Ávila DG, Bernal-Macías S, Parra MJ, et al. Prevalence of osteoporosis in Colombia: data from the national health registry from 2012 to 2018. Reumatol Clin. 2021;17:570–574.
   PubMed Web of Science ®Google Scholar
• Rosselli D, Pantoja-Ruiz C. SISPRO: the administrative database of the Colombian healthcare system. Acta Neurol Colomb. 2022;38:187–190.
   Google Scholar
• Piñeros M, Abriata MG, de Vries E, et al. Progress, challenges and ways forward supporting cancer surveillance in Latin America. Int J Cancer. 2021;149:12–20.
   PubMed Web of Science ®Google Scholar
• Ramírez-Barbosa P, Acuña Merchán L. Cancer risk management in Colombia, 2016. Colomb Med (Cali). 2018;49:128–134.
   PubMed Web of Science ®Google Scholar
• de la Vega M, da Silveira de Carvalho HM, Ventura Ríos L, et al. The importance of rheumatology biologic registries in Latin America. Rheumatol Int. 2013;33:827–835.
   PubMed Web of Science ®Google Scholar
• Curioso WH, Espinoza-Portilla E. Marco conceptual para el fortalecimiento de los sistemas de información en salud en el Perú. Rev Peru Med Exp Salud Publica. 2015;32:335–342.
   PubMedGoogle Scholar
• Plazzotta F, Luna D, González Bernaldo de Quirós F. Sistemas de información en salud: Integrando datos clínicos en diferentes escenarios y usuarios. Rev Peru Med Exp Salud Publica. 2015;32:343–351.
   PubMedGoogle Scholar
• Valencia O, Lopes G, Sánchez P, et al. Incidence and prevalence of cancer in Colombia: the methodology used matters. J Glob Oncol. 2018;1–7. DOI:10.1200/JGO.17.00008
   PubMedGoogle Scholar
• Mendivil CO, Amaya-Montoya M, Hernández-Vargas JA, et al. Achievement of treatment goals among adults with diabetes in Colombia, 2015-2019: results from a national registry. Diabet Res Clin Pract. 2022;186:109823.
   PubMed Web of Science ®Google Scholar
• Pereira LC, Sturzenegger DVR, Ortiz J, et al. Challenges in the regulation of high-cost treatments: an overview from Brazil. Value Health Reg Issues. 2019;20:191–195.
   PubMedGoogle Scholar
• Rodrigues T, Lockwood C, Ando G. International reference pricing expands reach in leading Latin American countries. Value Health. 2017;20:A905–6.
   Web of Science ®Google Scholar
• Gaviria A, González CP, Muñoz CG, et al. El debate de la regulación de medicamentos biotecnológicos: Colombia en el contexto internacional. Rev Panam Salud Publica. 2016;40:40–47.
   PubMed Web of Science ®Google Scholar
• Prieto-Pinto L, Garzón-Orjuela N, Lasalvia P, et al. International experience in therapeutic value and value-based pricing: a rapid review of the literature. Value Health Reg Issues. 2020:23;37–48. DOI:10.1016/j.vhri.2019.11.008
   PubMedGoogle Scholar
• Mejía A, Gilardino R, Kristensen FB, et al. Value-based pricing in Latin America: how far away are we? Value Health Reg Issues. 2018;17:219–223.
   PubMedGoogle Scholar
• Gilardino RE, Mejía A, Guarín D, et al. Implementing health technology assessments in Latin America: looking at the past, mirroring the future. Value Health Reg Issues. 2020;23:6–12.
   PubMedGoogle Scholar
• Novaes HM, Soárez PC. Health technology assessment (HTA) organizations: dimensions of the institutional and political framework. Cad Saude Publica. 2016;32:e00022315.
   Web of Science ®Google Scholar
• de L Horst MM, Soler O, Horst MMLDL. Fundo Estratégico da Organização Pan-Americana da Saúde: mecanismo facilitador para melhorar o acesso aos medicamentos. Rev Panam Salud Pública. 2010;27:43–48.
   PubMedGoogle Scholar
• Homedes N, Ugalde A. Improving access to pharmaceuticals in Brazil and Argentina. Health Policy Plan. 2006;21(2):123–131.
   PubMed Web of Science ®Google Scholar
• Nunn AS, Fonseca EM, Bastos FI, et al. Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. PLOS Med. 2007;4(11):e305. DOI:10.1371/journal.pmed.0040305
   PubMed Web of Science ®Google Scholar
• Varón A, Santos L, Tapias M, et al. Colombian experience in the treatment of hepatitis C with direct-acting antiviral agents. Med (B Aires). 2019;79:29–36.
   PubMed Web of Science ®Google Scholar
• Moye-Holz D, van Dijk JP, Reijneveld SA, et al. The impact of price negotiations on public procurement prices and access to 8 innovative cancer medicines in a middle-income country: the case of Mexico. Value Health Reg Issues. 2019;20:129–135.
   PubMedGoogle Scholar
• Teran E, Gomez H, Hannois D, et al. Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective. Lancet Oncol. 2022;23:e348–58.
   PubMed Web of Science ®Google Scholar
• Kowalski SC, Benavides JA, Roa PAB, et al. PANLAR consensus statement on biosimilars. Clin Rheumatol. 2019;38:1485–1496.
   PubMed Web of Science ®Google Scholar
• Garcia R, Araujo DV. The regulation of biosimilars in Latin America. Curr Rheumatol Rep. 2016;18:16.
   PubMed Web of Science ®Google Scholar
• Generics and Biosimilars Initiative (GaBi). Regulatory landscape for biosimilars in Latin America. Available at: https://gabionline.us7.list-manage.com/track/click?u=ce419cf98331051ad0197db2d&id=b555f4388d&e=5ac030bedc Accessed on Oct 3, 2022
   Google Scholar
• Wolff-Holz E, Tiitso K, Vleminckx C, et al. Evolution of the EU biosimilar framework: past and future. BioDrugs. 2019;33(6):621–634. DOI:10.1007/s40259-019-00377-y
   PubMed Web of Science ®Google Scholar
• Ortiz-Prado E, Ponce-Zea J, Vasconez JE, et al. Current trends for biosimilars in the Latin American market. GaBi J. 2020;9:64–74.
   Google Scholar
• Soto E. Accesibilidad a la medicina de alto costo: La experiencia de Uruguay. Rev Costarric Cardiol. 2011;13:5–11.
   Google Scholar
• Armijo N, Manuel E, Zamorano P, et al. Analisis del proceso de evaluación de tecnologías sanitarias del sistema de protección financiera para diagnósticos y tratamientos de alto costo en Chile (Ley Ricarte Soto). Value Health Reg Issues. 2022;22:95–101.
   Google Scholar
• Parra-Baltazar I, Pinto-Dongo C, Quispe-Iporra S. Ley de cobertura universal de enfermedades de alto costo. Rev Peru Med Exp Salud Publica. 2016;33:379–380.
   PubMedGoogle Scholar
• Pinto D, Moreno-Serra R, Cafagna G, et al. Un gasto eficiente para vidas más sanas. In: Izquierdo A, Pessino C, Vuletin G., (Eds.) (WA) DC: Banco Interamericano de Desarrollo; 2018. p. 263–300.
   Google Scholar
• Hernández-Vásquez A, Rojas-Roque C, Vargas-Fernández R, et al. Measuring out-of-pocket payment, catastrophic health expenditure and the related socioeconomic inequality in Peruvian households between 2008 and 2017. J Prev Medicine Public Health. 2020;53:266–274.
   PubMedGoogle Scholar
• Espinosa O, Rodríguez-Lesmes P, Orozco L, et al. Estimating cost-effectiveness thresholds under a managed healthcare system: experiences from Colombia. Health Policy Plan. 2022;37:359–368. DOI:10.1093/heapol/czab146
   PubMed Web of Science ®Google Scholar